Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR)

Sven F Seys; Josje Otten; Joost de Kinderen; Giulia Bettio; Alexandros Andrianakis; Isam Alobid; Carlo Cavaliere; P. W. Hellings; L. van Gerven; Valérie Hox; Claire Hopkins; Anette Drøhse Kjeldsen; Sven Schneider; PV Tomazic; Z. Diamant; Julia Eckl-Dorna; Wytske J. Fokkens; Clemens Holzmeister; Kenneth H. Larsen; Anu Laulajainen-Hongisto; Valerie Lund; Gert Mariën; Simonetta Masieri; G. Mortuaire; Mathilde Moyaert; Joaquim Mullol; Camilo Rodriguez van Strahlen; Marco de Vincentiis; Martin Wagenmann; Sietze Reitsma; C Bachert

doi:10.1016/j.waojou.2026.101365

Key Points

The aim is to evaluate the criteria for biologic treatment in chronic rhinosinusitis with nasal polyps based on established international guidelines.
Evaluated patients at outpatient ENT clinics across 10 tertiary centers in 7 European countries.
Utilized the Galenus Health mobile application for monitoring disease in patients.
Assessed the proportion of patients meeting biologic treatment criteria according to EUFOREA 2021 and EPOS/EUFOREA 2023 recommendations.
Out of 281 recruited CRS patients, 227 were diagnosed with chronic rhinosinusitis with nasal polyps.
21 patients with prior biologic use were excluded, highlighting the specific patient cohort considered for evaluation.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

This evaluation assesses biologic treatment criteria in chronic rhinosinusitis patients, suggesting variations in international recommendations influence treatment accessibility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seys et al. (2026) studied this question.

synapsesocial.com/papers/69c4cc37fdc3bde44891777f https://doi.org/10.1016/j.waojou.2026.101365

View Full Paper

Ask AI

Bookmark

Share

Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR)

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR)

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from World Allergy Organization Journal

Keep reading

More related papers

More from World Allergy Organization Journal